A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients - Preliminary findings
A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients - Preliminary findings
复制标题
DOI：
10.1016/s0740-5472(97)00226-2
复制
发表时间：
1998-05-01
影响因子：
3.9
通讯作者：
Kosten, TR
中科院分区：
文献类型：
--
作者：
Avants, SK;Margolin, A;Kosten, TR
继续使用阿片受体激动剂的艾滋病毒血清阳性阿片类药物依赖患者如果继续使用可卡因并从事其他高危行为，可能会受益于加强的治疗服务；然而，目前指导此类服务制定的数据很少。我们报告了一项初步研究，其中为 6 名 HIV 血清阳性阿片类药物和可卡因依赖患者提供了为期 12 周的综合药物/心理社会治疗计划，该计划是专为满足 HIV 血清阳性吸毒者的治疗需求而制定的。该计划包括丁丙诺啡（12 毫克/天）、安非他酮（150 毫克/天）和每周两次的手动指导团体治疗。结果显示，静脉注射可卡因的使用、对可卡因的渴望和抑郁症状显着减少。对八名接受标准美沙酮维持治疗的艾滋病毒血清阳性患者的结果进行事后比较，发现接受标准护理的患者没有任何改善。可能有必要对艾滋病毒血清阳性患者的强化药物治疗方案进行对照调查。 (C) 1998 爱思唯尔科学公司。
HIV-seropositive opioid-dependent patients maintained on an opiate-agonist who continue to use cocaine and to engage in other high-risk behaviors may benefit from enhanced treatment services; however, there is currently little data to guide the formulation of such services. We report on a preliminary study in which six HIV-seropositive opioid- and cocaine-dependent patients were provided a 12-week comprehensive pharmacologic/psychosocial treatment program developed specifically to meet the treatment needs of HIV-seropositive drug users. This program was comprised of buprenorphine (12 mg/day), bupropion (150 mg/day) and twice weekly manual-guided group therapy. Results showed significant decreases in intravenous cocaine use, cocaine craving, and symptoms of depression. A post-hoc comparison to outcomes of eight HIV-seropositive patients receiving standard methadone-maintenance found no improvements for patients receiving standard care. Controlled investigation of enhanced drug treatment programs for HIV-seropositive patients may be warranted. (C) 1998 Elsevier Science Inc.